Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Eplerenone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 known ✓ | P08235 | 3/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 5/20 | 1.00 |
| ▸ | PGR | P06401 | 5/20 | 1.00 |
| ▸ | AR | P10275 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.45 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.45 |
| ▸ | HTR2B | P41595 | 2/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eplerenone SCHEMBL14567750 | 1.00 | NR3C1 (1.00) | NR3C1PGRARNR3C2ALDH1A1 | |
| Eplerenone SCHEMBL685681 | 1.00 | NR3C1 (1.00) | NR3C1PGRARNR3C2ALDH1A1 | |
| Eplerenone SCHEMBL17993628 | 1.00 | NR3C1 (1.00) | NR3C1PGRARNR3C2ALDH1A1 | |
| Eplerenone SCHEMBL18382990 | 1.00 | NR3C1 (1.00) | NR3C1PGRARNR3C2ALDH1A1 | |
| Eplerenone SCHEMBL14571282 | 1.00 | NR3C1 (1.00) | NR3C1PGRARNR3C2ALDH1A1 | |
| Eplerenone SCHEMBL14284883 | 1.00 | NR3C1 (1.00) | NR3C1PGRARNR3C2ALDH1A1 | |
| Eplerenone SCHEMBL8175261 | 1.00 | NR3C1 (1.00) | NR3C1PGRARNR3C2ALDH1A1 | |
| Eplerenone SCHEMBL14565703 | 1.00 | NR3C1 (1.00) | NR3C1PGRARNR3C2ALDH1A1 | |
| Eplerenone SCHEMBL19887682 | 1.00 | NR3C1 (1.00) | NR3C1PGRARNR3C2ALDH1A1 | |
| Eplerenone SCHEMBL8445849 | 1.00 | NR3C1 (1.00) | NR3C1PGRARNR3C2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 809 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| WO-2009084040-A1 | ONCE A DAY FORMULATION OF ANGIOTENSIN RECEPTOR BLOCKERS | RUBICON RESEARCH PRIVATE LIMITED (IN) | 2009-07-09 | — | — | WO | claimed |
| WO-2007053406-A1 | COMBINATIONS OF ANTIHYPERTENSIVE AND CHOLESTEROL LOWERING AGENTS | NOVARTIS AG (CH) | 2007-05-10 | — | — | WO | claimed |
| CN-1780823-A | Heteroaromatic pentacyclic compound and medicinal use thereof | JAPAN TOBACCO INC (JP) | 2006-05-31 | — | — | CN | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-6984633-B2 | Method to treat cardiofibrosis with a combination therapy of an angiotensin II antagonist and epoxymexrenone | G.D SEARLE & CO. (US) | 2006-01-10 | — | — | US | claimed |
| EP-1558265-A1 | CARDIOVASCULAR PROTECTION USING ANTI-ALDOSTERONIC PROGESTINS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-08-03 | — | — | EP | claimed |
| EP-1303308-A2 | ALDOSTERONE ANTAGONIST AND CYCLOOXYGENASE-2 INHIBITOR COMBINATION THERAPY TO PREVENT OR TREAT INFLAMMATION-RELATED CARDIOVASCULAR DISORDERS | Pharmacia Corporation (US) | 2003-04-23 | — | — | EP | claimed |
| US-20020111337-A1 | Use of an aldosterone receptor antagonist to improve cognitive function | PHARMACIA CORPORATION | 2002-08-15 | — | — | US | claimed |
| EP-0730458-B1 | USE OF ALDOSTERONE ANTAGONISTS TO INHIBIT MYOCARDIAL FIBROSIS | UNIV MISSOURI (US) | 2002-03-20 | — | — | EP | claimed |
| WO-2002017895-A2 | USE OF AN ALDOSTERONE RECEPTOR ANTAGONIST TO IMPROVE COGNITIVE FUNCTION | PHARMACIA CORPORATION (US) | 2002-03-07 | — | — | WO | claimed |
| WO-2002009683-A2 | ALDOSTERONE BLOCKER THERAPY TO PREVENT OR TREAT INFLAMMATION-RELATED DISORDERS | PHARMACIA CORPORATION (US) | 2002-02-07 | — | — | WO | claimed |
| WO-2002009759-A2 | ALDOSTERONE ANTAGONIST AND CYCLOOXYGENASE-2 INHIBITOR COMBINATION THERAPY TO PREVENT OR TREAT INFLAMMATION-RELATED CARDIOVASCULAR DISORDERS | PHARMACIA CORPORATION (US) | 2002-02-07 | — | — | WO | claimed |
| US-6245755-B1 | ADMINISTERING EPOXYMEXRENONE WITH INCREASING SODIUM EXCRETION | CURATORS OF THE UNVERSITY OF MISSOURI | 2001-06-12 | — | — | US | claimed |
| US-6008210-A | ADMINISTERING EPOXYMEXRENONE | CURATORS OF THE UNIVERSITY OF MISSOURI, THE | 1999-12-28 | — | — | US | claimed |
| EP-0730458-A1 | USE OF ALDOSTERONE ANTAGONISTS TO INHIBIT MYOCARDIAL FIBROSIS | CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 1996-09-11 | — | — | EP | claimed |
| WO-1995015166-A1 | USE OF ALDOSTERONE ANTAGONISTS TO INHIBIT MYOCARDIAL FIBROSIS | CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 1995-06-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111337-A1 | Use of an aldosterone receptor antagonist to improve cognitive function | NR3C2, MC2R, AGTR1 | NR3C2 1/4885NR3C1 8/4885PGR 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.